Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Indivior Pharmaceuticals, Inc. - Common Stock (NQ:INDV)

35.90 -0.09 (-0.25%)
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Indivior Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Indivior Q2 2026 Earnings Call: Complete Transcript ↗
Indivior (NASDAQ:INDV) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For... 
Via Benzinga
Topics Earnings
News headline image
Why Supernus Pharmaceuticals Stock Topped the Market Today ↗
It's effecting a "merger of equals" with a peer. 
Via The Motley Fool
News headline image
Indivior Q2 Earnings Call Highlights ↗
Supernus Pharmaceuticals and Indivior (NASDAQ:INDV) announced plans to combine in an all-stock, tax-free merger of equals that the companies said would create a central nervous system-focused... 
Via MarketBeat
Topics Earnings
INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Shows Breakout Setup With Perfect Technical Strength Score ↗
Via Chartmill
News headline image
Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry? ↗
Indivior, a leader in opioid dependence therapies, reported a notable insider sale following a year of exceptional share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
Indivior Pharmaceuticals (NASDAQ:INDV) Passes Minervini Trend Template and High Growth Momentum Screen ↗
Via Chartmill
Indivior Pharmaceuticals Inc (NASDAQ:INDV) Smashes Q1 Estimates and Lifts Full-Year Outlook as SUBLOCADE Sales Surge ↗
Via Chartmill
News headline image
What to Know About This Fund's $74.8 Million Indivior Sale ↗
Indivior develops buprenorphine-based treatments for opioid dependence, serving markets in the US, UK, and worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200% ↗
Indivior develops buprenorphine-based therapies for opioid dependence, serving healthcare providers and treatment centers worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Know About This Fund's $61.5 Million Exit From Ecovyst Amid a 75% Stock Rally ↗
Ecovyst delivers catalysts and sulfuric acid services to global refining and chemical industries with advanced process solutions. 
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
Indivior Pharmaceuticals Inc (NASDAQ:INDV) Shows High Growth Momentum and Technical Breakout Potential ↗
Via Chartmill
Indivior Pharmaceuticals Inc (NASDAQ:INDV) Surpasses Q4 2025 Estimates and Provides Strong 2026 Outlook ↗
Via Chartmill
News headline image
Why One Fund Made a $23 Million Bet on This Addiction-Treatment Stock Amid a Staggering Rally ↗
Indivior develops proprietary treatments for opioid dependence, generating revenue from specialty pharmaceuticals across global markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Indivior (INDV) Q1 2026 Earnings Transcript ↗
Indivior (INDV) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Divisadero Dumps Stride Stock ↗
Stride delivers technology-driven education solutions for K–12 and adult learners, serving schools, districts, and employers nationwide. 
Via The Motley Fool
Topics Regulatory Compliance
INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Presents a High-Growth Momentum and Technical Setup Case ↗
Via Chartmill
INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Presents a High-Growth Momentum Breakout Setup ↗
Via Chartmill
News headline image
Indivior (INDV) Q4 2025 Earnings Call Transcript ↗
Indivior (INDV) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Vistance Networks Stock Up 250%. Here's Why a $40 Million Position Signals a Post-Divestiture Bet ↗
Vistance Networks delivers connectivity and network solutions for telecom, data centers, and enterprise clients worldwide. 
Via The Motley Fool
News headline image
Array Stock Down 25%, But This $17.3 Million Buy Signals Confidence Amid Big Revenue Growth ↗
Array Digital Infrastructure delivers wireless services and device sales to consumers, businesses, and government clients nationwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Enviri Stock Up 120% as $43 Million Buy Makes It a Top Holding in This Portfolio ↗
Enviri delivers environmental and specialty waste solutions for industrial clients through long-term contracts and value-added products. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Integer Stock Down 38%, but One Fund Just Bet $40 Million on a Turnaround ↗
Integer Holdings supplies medical device components and finished products to major OEMs in cardiac, neuro, and surgical markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Mangrove Partners Loads Up Flywire With 2.9 Million Shares ↗
The new holding places Flywire outside the fund’s top five positions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
INDIVIOR PLC (NASDAQ:INDV) Presents a High-Growth Momentum and Technical Breakout Setup ↗
INDIVIOR stock combines high-growth earnings momentum with a strong technical uptrend and a current bull flag setup for a potential breakout. 
Via Chartmill
News headline image
This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table ↗
When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bardin Hill Dumps 349,000 Shares of Frontier Communicaitons Stock Worth $12.7 Million ↗
The position previously accounted for 7.48% of fund AUM as of the prior quarter. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Millrose Properties Stock Has Surged 48% Since February Debut — So Why Did One Investor Sell a $23 Million Stake? ↗
A newly public real-estate platform is putting up numbers that look far more seasoned than its age. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Investor Bought $67.5 Million in Array Digital Infrastructure Stock ↗
One fund just made a bold bet on a telecom stock undergoing a big transformation 
Via The Motley Fool
News headline image
Why One Value Fund Has a $101 Million Bet on Indivior Stock Amid a 212% Surge ↗
This fund just doubled down on a stock that’s suddenly delivering the earnings momentum it’s promised for years. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Value Fund Just Bought $30 Million of a Diagnostics Stock Down 90% From Pandemic-Era Highs ↗
A beaten-down diagnostics stock is quietly tightening margins and drawing fresh institutional conviction—here’s what that means for long-term investors. 
Via The Motley Fool
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.